|
Real-time Estimate
Cboe BZX
01:29:57 09/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 810.31 USD | -2.10% |
|
-1.66% | +4.96% |
| Market Cap | 8.27TCr 7.11TCr 6.69TCr 6.1TCr 11TCr 7,83600Cr 11TCr 79TCr 31TCr 4,00500Cr 31TCr 30TCr 12,74500Cr | P/E 2026 * |
19.2x | P/E 2027 * | 16.4x |
|---|---|---|---|---|---|
| Enterprise Value | 7.58TCr 6.52TCr 6.13TCr 5.59TCr 10TCr 7,18500Cr 10TCr 73TCr 28TCr 3,67200Cr 28TCr 28TCr 11,68600Cr | EV / Sales 2026 * |
4.48x | EV / Sales 2027 * | 3.91x |
| Free-Float |
71.06% | Yield 2026 * |
0.47% | Yield 2027 * | 0.54% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REGN | Delayed | |
CBOE
| REGN | Real-time | |
|
Tradegate
| RGO | Real-time | |
|
Boerse Muenchen
| RGO | Real-time | |
|
Mexican S.E.
| REGN * | End-of-day quote | |
|
Xetra
| RGO | End-of-day quote | |
|
London S.E.
| 0R2M | Delayed | |
|
Deutsche Boerse AG
| RGO | Delayed | |
|
Borsa Italiana
| 1REGN | End-of-day quote | |
|
Wiener Boerse
| REGN | End-of-day quote | |
|
Börse Stuttgart
| RGO | Delayed | |
|
Lima
| REGNUS | End-of-day quote |
Last Transcript : Regeneron Pharmaceuticals, Inc.
| 1 day | -2.12% | ||
| 1 week | -1.66% | ||
| Current month | +1.39% | ||
| 1 month | +0.26% | ||
| 3 months | +32.52% | ||
| 6 months | +3.66% | ||
| Current year | +4.96% |
| 1 week | 799.42 |  | 859.34 |
| 1 month | 775.83 | | 859.34 |
| Current year | 591.52 | | 859.34 |
| 1 year | 541 | | 859.34 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 03/09/26 | Sell | Executive/Senior Manager | -1,131 | 0.0011% | ||
| 02/09/26 | Exercice | Director | 1,200 | 0.0012% | ||
| 19/08/26 | Exercice | General Counsel | 33,583 | 0.0326% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.10% | -1.66% | +45.08% | -2.47% | 8.27TCr | |
| +0.94% | +1.88% | -16.46% | -34.82% | 5.99TCr | |
| -3.11% | -8.87% | +466.17% | +30.60% | 5.81TCr | |
| -1.77% | -5.14% | -9.07% | +29.36% | 5.03TCr | |
| -1.62% | -3.90% | 0.00% | +149.76% | 4.66TCr | |
| -3.86% | -1.69% | +50.25% | -18.00% | 3.26TCr | |
| -1.84% | -0.57% | +43.60% | +94.28% | 2.57TCr | |
| -1.09% | -3.47% | -2.81% | +183.45% | 2.25TCr | |
| +1.56% | -0.09% | +65.58% | +110.60% | 1.63TCr | |
| -3.15% | -9.92% | -24.27% | +747.29% | 1.48TCr | |
| Average | -1.60% | -0.23% | +61.81% | +129.01% | 4.1TCr | |
| Weighted average by Cap. | -1.65% | +0.82% | +80.04% | +65.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.69TCr 1.45TCr 1.37TCr 1.25TCr 2.33TCr 1,60400Cr 2.34TCr 16TCr 6.27TCr 82TCr 6.35TCr 6.22TCr 2,60900Cr | 1.84TCr 1.58TCr 1.49TCr 1.36TCr 2.54TCr 1,74600Cr 2.55TCr 18TCr 6.83TCr 89TCr 6.92TCr 6.77TCr 2,84000Cr |
| Net income | 477.34Cr 410.41Cr 386.11Cr 352.36Cr 657.57Cr 45TCr 660.97Cr 4.57TCr 1.77TCr 23TCr 1.79TCr 1.75TCr 74TCr | 544.54Cr 468.19Cr 440.47Cr 401.97Cr 750.15Cr 52TCr 754.02Cr 5.22TCr 2.02TCr 26TCr 2.04TCr 2TCr 84TCr |
| Net Debt | -686.84Cr -590.54Cr -555.58Cr -507.01Cr -946.17Cr -65TCr -951.06Cr -6.58TCr -2.55TCr -33TCr -2.58TCr -2.52TCr -1,05900Cr | -1.06TCr -907.42Cr -853.69Cr -779.06Cr -1.45TCr -1,00100Cr -1.46TCr -10TCr -3.91TCr -51TCr -3.96TCr -3.88TCr -1,62700Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/26/09 | $810.48 | -2.08% | 3,34,223 |
| 04/26/04 | $827.72 | -1.87% | 5,61,170 |
| 03/26/03 | $843.47 | -1.00% | 4,96,255 |
| 02/26/02 | $852.03 | +3.42% | 7,49,453 |
| 01/26/01 | $823.82 | +3.10% | 6,82,806 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
